newsare.net
French healthcare group Sanofi has agreed to buy U.S. peer Bioverativ for US$11.6 billion, in a deal which Sanofi said would boost its earnings and strengthen its presence in the field of treatment for rare diseases.Sanofi confirms deal to buy Bioverativ for US$11.6 billion
French healthcare group Sanofi has agreed to buy U.S. peer Bioverativ for US$11.6 billion, in a deal which Sanofi said would boost its earnings and strengthen its presence in the field of treatment for rare diseases. Read more